Ocean Biomedical, Inc. Stock

Equities

OCEA

US67644C1045

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-12 pm EDT 5-day change 1st Jan Change
2.235 USD +1.36% Intraday chart for Ocean Biomedical, Inc. -15.50% +238.64%
Sales 2023 * - Sales 2024 * - Capitalization 76.18M
Net income 2023 * -92M Net income 2024 * -32M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.73 x
P/E ratio 2024 *
-2.51 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 26.82%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.36%
1 week-15.50%
Current month-40.95%
1 month-46.53%
3 months+255.16%
6 months+8.50%
Current year+238.64%
More quotes
1 week
2.18
Extreme 2.175
2.64
1 month
2.18
Extreme 2.175
4.97
Current year
0.52
Extreme 0.52
7.79
1 year
0.52
Extreme 0.52
12.08
3 years
0.52
Extreme 0.52
26.60
5 years
0.52
Extreme 0.52
26.60
10 years
0.52
Extreme 0.52
26.60
More quotes
Date Price Change Volume
24-04-12 2.235 +1.36% 324,473
24-04-11 2.205 -9.26% 431,494
24-04-10 2.43 -1.62% 337,653
24-04-09 2.47 -5.00% 228,790
24-04-08 2.6 -1.70% 306,204

Delayed Quote Nasdaq, April 12, 2024 at 04:00 pm EDT

More quotes
Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
More about the company